The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by Chardan Capital on March 9, 2026. The analyst firm set a price target for $38.00 expecting DYN to rise to within 12 months (a possible 117.58% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Dyne Therapeutics (NASDAQ:DYN) was provided by Chardan Capital, and Dyne Therapeutics maintained their buy rating.

The last upgrade for Dyne Therapeutics Inc happened on December 10, 2025 when Oppenheimer raised their price target to $40. Oppenheimer previously had a perform for Dyne Therapeutics Inc.

The last downgrade for Dyne Therapeutics Inc happened on October 10, 2025 when Oppenheimer changed their price target from $13 to $13 for Dyne Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on March 9, 2026 so you should expect the next rating to be made available sometime around March 9, 2027.

While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a maintained with a price target of $38.00 to $38.00. The current price Dyne Therapeutics (DYN) is trading at is $17.47, which is out of the analyst’s predicted range.